Appetite Control Supplement Recalled Due to Confirmed DMAA

Published Online: Monday, August 11, 2014
Follow Pharmacy_Times:
Regeneca Worldwide, a division of VivaCeuticals, Inc, has launched a voluntary nationwide recall of RegeneSlim following an FDA analysis that confirmed the presence of DMAA in the appetite control dietary supplement.  

Also known as 1,3-dimethylamylamine, methylhexanamine, or geranium extract, DMAA is commonly used as a stimulant, pre-workout, and weight loss ingredient in dietary supplements. DMAA is potentially dangerous to health because it can narrow blood vessels and arteries, which can cause a rise in blood pressure or other cardiovascular problems, such as shortness of breath, arrhythmias, tightening in the chest, and heart attack, the FDA warned in the recall announcement.

As a result, consumers who have purchased RegeneSlim from lot numbers EX0616R15814 and 11414RE5516 are urged to immediately stop using the product and return it to the place of purchase for a full exchange. Consumers should also contact their physician or health care provider if they experience any problems that may be related to taking or using RegeneSlim. Although no illnesses related to the supplement have been reported to date, Regeneca continues its investigation as to what caused the problem.

RegeneSlim is purchased by and distributed through a direct sales force within the United States and Puerto Rico, and through online sales, for both personal consumption and retail sales. The supplement is packaged in green and white sachets that contain 2 capsules, and the word “RegeneSlim” is displayed prominently on the front of each sachet.

Adverse reactions or quality problems experienced with the use of RegeneSlim may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.
Related Articles
Implementing physician-pharmacist collaborative management methods reduces asthma-related emergency department visits.
Selenium and vitamin E supplementation will not prevent cataracts in men, a new study suggests.
Combining 2 classes of COPD medications leads to better outcomes for older adults with comorbid asthma.
The FDA today approved dulaglutide (Trulicity), a once-weekly injectable therapy indicated to improve blood sugar control in adults with type 2 diabetes.
Latest Issues
$auto_registration$